secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0000950170-24-127927
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet opens ADI-270 Phase 1 enrollment in ccRCC, doses first lupus nephritis patient with ADI-001
--------------------------------------------------------------------------------

- Enrollment opened for Phase 1 trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma; preliminary data expected 1H25.
- First lupus nephritis patient dosed in Phase 1 trial of ADI-001; preliminary clinical data in LN anticipated 1H25.
- ADI-001 received FDA Fast Track Designation for relapsed/refractory class III or IV lupus nephritis.
- Company expects to begin enrollment in SLE, SSc, IIM, SPS in 1Q25 and AAV in 2H25.
- ADI-270 is the first gamma delta CAR T cell therapy for solid tumors to enter clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024127927/0000950170-24-127927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024127927/acet-20241118.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer